The turnabout for each came after both insurers ended automatic coverage of the blockbuster GLP-1 weight loss drugs such as Wegovy and Zepbound solely for the treatment of obesity
Its purpose is to manage blood sugar levels after meals, but it can also affect appetite and weight loss, hence why these medications are often used to treat obesity
Newer FDA approvals semaglutide for cardiovascular risk reduction, tirzepatide for obstructive sleep apnea are gradually widening what Medicare and commercial plans will pay for, and they are sometimes the only route to coverage where a weight-loss exclusion applies
Key deficiencies that may contribute to hair loss include: Protein : Insufficient protein intake impairs keratin production, the structural protein of hair Iron : Low iron stores and anemia commonly cause diffuse hair shedding Zinc : Essential for hair follicle function and protein synthesis B vitamins : Support cellular metabolism in rapidly dividing hair follicle cells Additionally, the gastrointestinal effects of GLP-1 medicationsincluding nausea, vomiting, and delayed gastric emptyingmay reduce nutritional intake even further
A further 54% of Canadian employers say they are not considering offering coverage for GLP-1 drugs for weight loss, while 24% are not sure and 17% are considering it, finds the International Federation of Employee Benefit Plans (IFEBP)
[10] In the U.S., more than 30% of adults, and 16% of children aged between two and 19 are overweight
.png)
